UBS Group
AVDL

UBS Group’s Avadel Pharmaceuticals AVDL Stock Holding History

UBS Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-344,933
Closed -$7.43M – 10473
2025
Q4 		$7.43M Sell
344,933
-333,048
-49% -$6.47M ﹤0.01% 3609
2025
Q3 		$10.4M Sell
677,981
-197,258
-23% -$2.57M ﹤0.01% 3261
2025
Q2 		$7.75M Sell
875,239
-419,393
-32% -$3.68M ﹤0.01% 3387
2025
Q1 		$10.1M Sell
1,294,632
-276,228
-18% -$2.31M ﹤0.01% 3025
2024
Q4 		$16.5M Buy
1,570,860
+963,556
+159% +$11.7M ﹤0.01% 2538
2024
Q3 		$7.96M Buy
607,304
+372,962
+159% +$5.68M ﹤0.01% 2588
2024
Q2 		$3.29M Buy
234,342
+220,812
+1,632% +$3.6M ﹤0.01% 3254
2024
Q1 		$229K Buy
13,530
+2,230
+20% +$33.2K ﹤0.01% 5765
2023
Q4 		$160K Sell
11,300
-134
-1% -$1.57K ﹤0.01% 5911
2023
Q3 		$118K Sell
11,434
-1,954
-15% -$26.2K ﹤0.01% 5724
2023
Q2 		$221K Buy
13,388
+2,717
+25% +$35.3K ﹤0.01% 5410
2023
Q1 		$97.7K Buy
10,671
+7,745
+265% +$63.7K ﹤0.01% 5925
2022
Q4 		$20.9K Sell
2,926
-9,029
-76% -$63.3K ﹤0.01% 7599
2022
Q3 		$60K Buy
11,955
+8,971
+301% +$49.4K ﹤0.01% 6163
2022
Q2 		$7K Sell
2,984
-323
-10% -$1.33K ﹤0.01% 8449
2022
Q1 		$23K Sell
3,307
-4,951
-60% -$34K ﹤0.01% 7279
2021
Q4 		$67K Sell
8,258
-4,243
-34% -$38.8K ﹤0.01% 6657
2021
Q3 		$122K Sell
12,501
-983
-7% -$7.74K ﹤0.01% 5685
2021
Q2 		$91K Buy
13,484
+6,616
+96% +$52.5K ﹤0.01% 5957
2021
Q1 		$63K Buy
6,868
+2,160
+46% +$17.5K ﹤0.01% 6321
2020
Q4 		$32K Buy
4,708
+733
+18% +$4.58K ﹤0.01% 6570
2020
Q3 		$20K Sell
3,975
-719
-15% -$5.23K ﹤0.01% 6296
2020
Q2 		$38K Buy
4,694
+1,469
+46% +$13K ﹤0.01% 6090
2020
Q1 		$26K Sell
3,225
-3,995
-55% -$30.7K ﹤0.01% 6319
2019
Q4 		$54K Buy
7,220
+2,770
+62% +$14.6K ﹤0.01% 6308
2019
Q3 		$18K Buy
4,450
+2,444
+122% +$6.12K ﹤0.01% 6792
2019
Q2 		$6K Buy
2,006
+1,902
+1,829% +$3.27K ﹤0.01% 7299
2019
Q1 		$0 Sell
104
-3,075
-97% -$6.96K ﹤0.01% 7718
2018
Q4 		$8K Sell
3,179
-2,838
-47% -$9.65K ﹤0.01% 7334
2018
Q3 		$26K Buy
6,017
+1,321
+28% +$7.13K ﹤0.01% 6628
2018
Q2 		$29K Buy
4,696
+3,487
+288% +$24.5K ﹤0.01% 6405
2018
Q1 		$8K Sell
1,209
-740
-38% -$6.51K ﹤0.01% 6993
2017
Q4 		$16K Buy
1,949
+1,895
+3,509% +$17.8K ﹤0.01% 6715
2017
Q3 		$1K Sell
54
-2,438
-98% -$23.3K ﹤0.01% 7555
2017
Q2 		$28K Buy
2,492
+2,362
+1,817% +$23.7K ﹤0.01% 6050
2017
Q1 		$2K Sell
130
-3,185
-96% -$31.8K ﹤0.01% 7270
2016
Q4 		$35K Buy
3,315
+1,459
+79% +$16K ﹤0.01% 6106
2016
Q3 		$23K Sell
1,856
-1,661
-47% -$21.7K ﹤0.01% 6186
2016
Q2 		$38K Buy
3,517
+1,731
+97% +$18.5K ﹤0.01% 5732
2016
Q1 		$19K Buy
1,786
+1,750
+4,861% +$17.4K ﹤0.01% 6229
2015
Q4 		$0 Sell
36
-720
-95% -$11.2K ﹤0.01% 8327
2015
Q3 		$12K Sell
756
-43,138
-98% -$950K ﹤0.01% 7134
2015
Q2 		$930K Buy
43,894
+9,742
+29% +$175K ﹤0.01% 3629
2015
Q1 		$614K Sell
34,152
-10,022
-23% -$157K ﹤0.01% 3961
2014
Q4 		$757K Buy
+44,174
New +$631K ﹤0.01% 3807

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

UBS Group's AVDL Position: Q1 2026 in Review

UBS Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 344,933 shares — an estimated $7.43M sold.

UBS Group first reported a position in AVDL in Q4 2014 and held it in 45 quarters. The position peaked at $16.5M in Q4 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • UBS Group reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • UBS Group sold 344,933 Avadel Pharmaceuticals shares in Q1 2026, an estimated $7.43M.
  • UBS Group first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 45 quarters.
  • UBS Group's Avadel Pharmaceuticals position peaked at $16.5M in Q4 2024.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.